CANREVALUE STAKEHOLDER CONSULTATIONS

On November 6th 2019, the CanREValue Engagement WG held the first Engagement Webinar with over 250 attendees joining. The slide decks & recordings from this session can be found here.

After the webinar, we initiated a stakeholder consultation on the Data WG Interim Report on November 13th 2019 and Policy WGs Interim Report on December 17th, 2019. We received over 20 responses for each of the reports from industry, patient representatives/groups, and academic researchers. We are pleased to announce our Methods WG Interim Report is newly posted as of March 23, 2020. We invite your feedback – please visit https://cc-arcc.ca/canrevalue-interim-methods-report/ for details.

Next Steps: The Data WG is working with the CanREValue Engagement WG and the CanREValue research team to address the stakeholder responses. The CanREValue Engagement WG is synthesizing responses to the Policy WG report and will share them with the relevant WG chairs and members. Feedback on the Methods WG Interim report will be accepted until April 19th, 2020. Please email us at CanREValue@cc-arcc.ca if you have any questions or need additional information.
MEMBER SPOTLIGHT – AMBICA PARMAR

**Q:** What is your research focused on, and what are your long-term career goals? My research interests are in health services research and health technology assessment. As a medical oncologist, I am particularly interested in the use of health technology assessment methods to address clinical and health policy decisions in cancer care.

**Q:** What aspect of the CanREValue project are you the most excited to work on? I am very excited to be working with the Planning & Drug Selection working group on the creation and implementation of a Multi-Criteria Decision Analysis (MCDA) rating tool that will help facilitate the prioritization of potential real-world evidence projects.

**Q:** What has been the most interesting aspect of this project for you so far? What I have found most educational through this experience has been the importance of “thinking-outside-the-box” when tackling new questions. The use of MCDA to assess the value of research projects is quite novel and through the current work, is revealing itself to be a valuable approach for the current objective.

**Q:** How can we reach you? You can connect over email at ambika.parmar@sunnybrook.ca or through CanREValue @ canrevalue@cc-arcc.ca
## WORKING GROUP UPDATES AND NEXT STEPS:

<table>
<thead>
<tr>
<th>Working Group</th>
<th>Updates &amp; Next Steps</th>
</tr>
</thead>
</table>
| RWE Planning and Drug Selection| **Updates:** Members developed MCDA weights with help from an MCDA expert  
• Members participated in a teleconference and applied the MCDA weights on an example RWE question.  
**Next Steps:**  
• Finalize the MCDA rating tool |
| RWE Data                       | **Updates:**  
• Held two interprovincial analysis meetings to discuss cohort creation and algorithm development  
• Continued contract discussions for data sharing  
**Next Steps:**  
• Continue with real-world analysis (cohort creation, survival analysis) in 9 provinces |
| RWE Methods                    | **Updates:**  
**Next Steps:**  
• Continue developing paper on methods for assessing survival |
| RWE Reassessment and Uptake    | **Updates:**  
• Held a teleconference discussing the potential barriers and facilitators for the uptake of reassessment recommendations  
**Next Steps:**  
• Continue developing the process for uptake of reassessment recommendations |
| Stakeholder Engagement         | **Updates:**  
• Launched stakeholder consultation for Interim Data Report and Interim Policy Report  
• Launched stakeholder consultation for Method Progress report  
**Next Steps:**  
• Respond to feed from stakeholder consultation |

## Recent Publications

*Introductory paper on the CanREValue Framework now available:*

Above: Kelvin Chan shares CanREValue work during the 2019 Canadian Cancer Research Conference Session Getting Real: The Expanding Role of Real-World Evidence (RWE) in Oncology. Session was chaired by Winson Cheung, and also included presentations from Annette Hay (Canadian Clinical Trials Group), Nicole Mittmann (CADTH), and John Kildea (McGill University).

CanREValue at #CADTH2020

- The following works were submitted to CADTH Symposium and were accepted as **oral** presentations:
  - Building a Reassessment Framework for Cancer Drugs: Lessons Learned from the CanREValue Collaboration Mock Reassessment Exercise
  - Mapping Canadian Data Assets to Conduct Real-World Studies: Lessons Learned from the CanREValue Real-World Evidence Data Working Group

Unfortunately, due to concerns with COVID-19, the in-person 2020 CADTH Symposium has been cancelled. We are waiting to hear from organizers about potential presentation opportunities and will keep you posted once we confirm how this work can be shared!

**Coming Soon!**

- Feedback & responses from stakeholder consultation
  - The responses to the feedback from the consultation will be posted on the CanREValue website
- Alternative options for in-person meeting:
  - We will explore alternative options for the in-person meeting, more information will be provided at a later date.